Stock vs Stock Comparison

Regeneron Pharmaceuticals, Inc. vs Johnson & Johnson

REGN wins the Tale of the Tape 5–3.

REGN$602.92
JNJ$222.89

🏆 Tale of the Tape

53
REGNJNJ
31.4%Profitability (Net Margin)28.5%
15.0xValuation (P/E)26.1x
11.5%Efficiency (ROIC)18.3%
4/9Health (Piotroski F)4/9
7.5Safety (Altman Z)4.0
1.0%Growth (Rev YoY)6.0%
0.74Risk (Sharpe 1Y)2.69
0.30xBalance Sheet (D/E)1.44x
4.82%FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.184
252-Day Correlation
0.182
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricREGNJNJ
Market Cap$64.5B$542.4B
P/E Ratio15.0x26.1x
Forward P/E11.4x17.7x
P/B1.99x6.68x
Dividend Yield0.61%2.38%
Beta0.300.26

Quantitative Metrics

MetricREGNJNJ
DCF Fair Value$591.14$134.24
DCF Upside-20.8%-43.6%
Piotroski F4/94/9
Altman Z7.533.97
Beneish M-2.55-2.27
FCF Yield4.82%3.25%
Net Debt/EBITDA-0.2x0.5x
ROIC11.5%18.3%
WACC7.9%7.7%
ROIC – WACC3.6pp10.5pp
Gross Margin85.4%67.9%
Net Margin31.4%28.5%
Rev Growth YoY1.0%6.0%
Sharpe (1Y)0.742.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio10%64%

REGN Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

REGN found in:

IBB6.67%
XLV1.21%
VHT1.18%
XBI0.96%
ONEV0.79%
DGRW0.72%
VFVA0.60%
QQQ0.44%
MGV0.36%
SCHG0.30%
VTV0.29%
IWD0.26%
SPYV0.22%
VONV0.22%
RSP0.20%
ONEO0.17%
ESGV0.16%
IVV0.13%
SCHX0.13%
VOO0.12%
SCHB0.12%
ITOT0.12%
SPLG0.11%
VONE0.11%
VTI0.11%
SPY0.10%
URTH0.10%
SPTM0.09%
ACWI0.08%
QUS0.08%
VT0.06%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

REGN vs JNJ: Head-to-Head Analysis

Regeneron Pharmaceuticals, Inc. (REGN) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, REGN leads 5–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, REGN generates a return on invested capital (ROIC) of 11.5% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between REGN and JNJ is 0.184, indicating low correlation, making them an effective diversification pair in a portfolio context.

REGN appears in 31 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, REGN or JNJ?

Our quantitative analysis compares REGN and JNJ across nine fundamental dimensions. REGN wins the Tale of the Tape 5–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are REGN and JNJ correlated?

The 252-day correlation between REGN and JNJ is 0.184. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.